PIA
SNDX icon

Piedmont Investment Advisors’s Syndax Pharmaceuticals SNDX Stock Holding History

Piedmont Investment Advisors’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-257
Closed -$2K – 2094
2018
Q2 		$2K Buy
+257
New +$2.52K ﹤0.01% 2630

Other funds holding SNDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Piedmont Investment Advisors's SNDX Position: Q3 2018 in Review

Piedmont Investment Advisors sold out of Syndax Pharmaceuticals (SNDX) in Q3 2018, closing a stake of 257 shares — an estimated $2K sold.

Piedmont Investment Advisors first reported a position in SNDX in Q2 2018 and held it in 1 quarter. The position peaked at $2K in Q2 2018. 75 funds tracked by Wall St. Rank hold SNDX as of Q3 2018.

  • Piedmont Investment Advisors reported no remaining Syndax Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
  • Piedmont Investment Advisors sold 257 Syndax Pharmaceuticals shares in Q3 2018, an estimated $2K.
  • Piedmont Investment Advisors first reported a position in Syndax Pharmaceuticals in Q2 2018 and held it in 1 quarter.
  • Piedmont Investment Advisors's Syndax Pharmaceuticals position peaked at $2K in Q2 2018.
  • 75 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q3 2018.

Based on Piedmont Investment Advisors's 13F filing for Q3 2018, filed 8 Nov 2018.